Rose Higgins, chief executive officer at HealthMyne, sits down with Sam to discuss the role radiomics is playing in cancer care. Our biology-guided radiotherapy will generate a plethora of new data that will one day become part of the data fabric to help us understand what is happening at both the molecular and biological level. This podcast dives into how radiomics can provide insights to better inform treatment decisions and what the future may hold.
All content for RefleXion Podcast is the property of RefleXion and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Rose Higgins, chief executive officer at HealthMyne, sits down with Sam to discuss the role radiomics is playing in cancer care. Our biology-guided radiotherapy will generate a plethora of new data that will one day become part of the data fabric to help us understand what is happening at both the molecular and biological level. This podcast dives into how radiomics can provide insights to better inform treatment decisions and what the future may hold.
RefleXion's Chief Business Officer, Thorsten Melcher Ph.D., and Chris Behrenbruch Ph.D, founder and CEO of Telix Pharmaceuticals, explore how holistic treatment strategies for metastatic cancer patients interact with the world of commerce. What is the role of radiopharmacueticals in the radiotherapy delivery? What influence does the design of clinical trials have on market authorization? Why would a company deliberately integrate with an existing therapy rather than replace it? Find out in th...
RefleXion Podcast
Rose Higgins, chief executive officer at HealthMyne, sits down with Sam to discuss the role radiomics is playing in cancer care. Our biology-guided radiotherapy will generate a plethora of new data that will one day become part of the data fabric to help us understand what is happening at both the molecular and biological level. This podcast dives into how radiomics can provide insights to better inform treatment decisions and what the future may hold.
